Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699461 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04699461: Clinical Trial Phase 2 study, sponsored by ADC Therapeutics S.A..
NCT04699461 is a Phase 2 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04699461, a Phase 2 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
Primary Outcome
CRR was defined as the percentage of participants who experienced a best overall response (BOR) of complete response (CR) assessed prior to any subsequent anticancer treatment.
Interventions
- DRUG Loncastuximab Tesirine
- DRUG Idelalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2022-11-25 |
| Phase | Phase 2 |
Why NCT04699461 stopped before completion
NCT04699461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Loncastuximab Tesirine is the first listed.
NCT04699461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04699461 about?
NCT04699461 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma". This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
What is the current status of trial NCT04699461?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-11-04. Estimated completion is 2022-11-25.
What interventions are being tested in trial NCT04699461?
The interventions under investigation include: Loncastuximab Tesirine (DRUG), Idelalisib (DRUG).
Who is sponsoring clinical trial NCT04699461?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04699461's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI